Best Genomics Companies in Australia
The 93 best Genomics companies in Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: SpeeDx.
Tracking the best Genomics companies in Australia by disclosed equity funding, this directory covers 93 ventures with a combined $329M raised — and the numbers tell you exactly where the momentum lives. SpeeDx leads the pack at $78M, followed by Benitec Biopharma at $71M, two companies that together account for nearly half the sector's total disclosed capital. The global genomics market sat at roughly $24.3B in 2021 and is forecast to reach $85.1B by 2030 at a 16.37% CAGR, driven by declining sequencing costs and surging demand for personalized medicine. I'd note that Australia's 93-company field looks lean against that global backdrop, which makes the funding concentration at the top even more telling.
So what's pulling investment right now? Hereditary disease genomics, pharmacogenomics and machine learning drug discovery are the hot themes this quarter, and the sector's getting harder to ignore at a macro level. Mukesh Ambani recently called genomics one of the forces shaping the next decade, which signals how far the conversation has moved beyond pure biotech circles. Active backers here include Yuuwa Capital, Flying Fox Ventures and business.gov.au, a mix that reflects both private conviction and government support as a genuine demand driver. No unicorns yet, but the structural tailwinds are real.
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Australia
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SpeeDx Provider of qPCR-based molecular diagnostics platform | $78M | 39 mo ago | Series C | 113 | Alison Todd Co-Founder | 4 signals ▼20% Announcements · Contracts · Capital raise | — | 5 partnerships |
| 2 | Benitec Biopharma Limited Developer of RNAi-based therapies for infectious, ocular, and genetic diseases | $71M | 26 mo ago | Public | 18 | — | 5 signals ▼64% Announcements · Leadership · IPO | 120 patents Engineered AAV gene‑therapy vectors and OPMD therapeutic reagents for muscle disease treatment | — |
| 3 | Clinical Genomics Biomarker-based blood tests for early cancer detection | $41M | 96 mo ago | Deadpooled | 50 | Susanne Pedersen Co-Founder & CSO | — | 256 patents Colorectal cancer epigenetic methylation biomarker panels for diagnostic testing | — |
| 4 | PYC Therapeutics Developer of the drug for retinal, liver and neuro-degenerative diseases | $30M | 37 mo ago | Public | 25 | Rohan Hockings CEO | 12 signals ▲1100% Capital raise · Leadership | 48 patents Peptide-based delivery systems for renal and neurogenetic therapeutic applications | — |
| 5 | Telix Pharma Developer of theranostic radiopharmaceuticals for imaging and treating cancer | $25M | 67 mo ago | Public | 234 | — | 40 signals Earnings · Lawsuit · Regulatory | — | 1 partnership · 1 award |
| 6 | Orchid Provider of a genetic test for determining the health risk of babies 16Funding top 41%Tech top 42%Global bottom 36%Growth bottom 35% All 5 signals ▾Fundingtop 41% Techtop 42% Globalbottom 36% Growthbottom 35% Marketbottom 21% Funding: Raised $16.5M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Tech: 25 technologies across 4/8 capability areas · Cloud: Cloudflare, Vercel rank vs industry peers · Fliar Intelligence Index 16/100 | $16M | 30 mo ago | Series A | 10 | — | — | — | — |
| 7 | Proteomics International Medical technology company at the forefront of predictive diagnostics and bio-analytical services | $16M | 28 mo ago | Public | — | Richard Lipscombe Co-Founder & Managing Director | — | — | — |
| 8 | Genetic Signatures Molecular diagnostic reagents and kits for pathogen detection | $11M | 117 mo ago | Public | — | — | — | 166 patents Isothermal nucleic acid amplification and molecular detection of microbial genetic material | 4 job openings |
| 9 | Antisense Therapeutics Developer of RNA-based antisense drugs | $10M | 67 mo ago | Public | 8 | — | — | 123 patents Antisense oligonucleotide therapies for neurological and muscular disorders | — |
| 10 | Minomic Non-invasive blood tests for cancer | $8M | 114 mo ago | Series A | 14 | Brad Walsh Founder & CEO | — | — | — |
| 11 | INOVIQ Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer | $6M | 8 mo ago | Public | 5 | Leearne Hinch CEO | — | 4 patents Polymer resin formulations and extracellular vesicle-based therapeutic/diagnostic technologies. | — |
| 12 | Nexgen Plants Provider of platform technology for developing virus-resistant plant varieties | $4M | 94 mo ago | Deadpooled | 2 | — | — | 10 patents Intragenic plant transformation vectors and recombinant DNA constructs for crop genetic improvement. | — |
| 13 | Avicena Systems Developer of biosecurity platform and hardware for pathogen testing | $3M | 28 mo ago | Funding Raised | 20 | Tony Fitzgerald Co-Founder & CEO | — | 22 patents High-throughput bioassay and pathogen/genetic screening instrumentation | 1 partnership |
| 14 | Microba Developer of microbiome-based drug discovery platform | $3M | 12 mo ago | Public | 72 | Gene Tyson Founder & Director | — | — | — |
| 15 | Rhythm Biosciences Developer diagnostic tests for the detection of cancer | $3M | 24 mo ago | Public | — | David Atkins Chief Executive Officer | — | — | 1 partnership |
| 16 | Mass Dynamics Provider of platform for proteomics and discovery scientists | $2M | 61 mo ago | Seed | 16 | Aaron Triantafyllidis Co-Founder | — | — | 1 launch |
| 17 | DArT Provider of genomic data production, software, and data analytics services | $1M | 96 mo ago | Funding Raised | — | Andrzej Kilian Founder | — | — | — |
| 18 | Fitgenes Personalised genome-based healthcare and wellness | $1M | 144 mo ago | Late Stage | 6 | Paul Beaver Co-Founder & CSO | — | — | — |
| 19 | Zip Diagnostics Developer of molecular diagnostic tests and instruments for infectious diseases | $750K | 62 mo ago | Funding Raised | — | Jack Richards Co-Founder | — | 7 patents Rapid point‑of‑care lateral flow diagnostic testing for biological and environmental samples | — |
| 20 | Nemgenix Developer of plant-resistant traits | $593K | 162 mo ago | Funding Raised | — | Sean Hird Co-Founder & CEO | — | — | — |
| 21 | Eugene Labs Provider of genetic-based health care services | $525K | 65 mo ago | Series A | 31 | Zoe Milgrom Co-Founder & Director | — | — | — |
Top 12 Genomics companies in Australia
#1
Public · Notting Hill, Victoria · founded 1983 · 5 employees$6.1Mraised▾
Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer. The company has an hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes.
- Oct 2025Post IPO$6.1M
#2
Public · Brisbane, Queensland · founded 2017 · 72 employees$2.9Mraised▾
Developer of microbiome-based drug discovery platform. The company uses human data and leading informatics approaches to connect microbial genotype to the human phenotype. It develops a pipeline for inflammatory bowel disease and Immuno-oncology diseases.
- Jun 2025Post IPO$9.3M
- Jun 2023Grant (prize money)—
- Jun 2019Series A$2.9M
#3
Public · Sydney, New South Wales · founded 1997 · 18 employees$70.5Mraised▾
Developer of RNAi-based therapies for infectious, ocular, and genetic diseases. The company specializes in genetic medicines that combine gene therapy with DNA-directed RNA interference (ddRNAi) for sustained gene silencing. The company targets chronic and life-threatening conditions like Oculopharyngeal Muscular Dystrophy (OPMD), where its lead candidate BB-301 aims to address moderate dysphagia through a single administration.
- Apr 2024Post IPO$40M
- Sep 2019Post IPO$2.2M
- Feb 2014Post IPO$28.3M
#4
Series C · Sydney, New South Wales · founded 2009 · 113 employees$78Mraised▾
Provider of qPCR-based molecular diagnostics platform. The company's products include multiplexed assays for HSV-1 and -2, VZV, and Syphilis, and detecting the presence of Mycoplasma genitalium as well as antibiotic resistance. The products are based on plexZyme technology where primers amplify target nucleic acid sequences and produce an amplicon.
- Feb 2023Series C$26M
- May 2021Grant (prize money)—
- Sep 2020Grant (prize money)—
- Feb 2020Series B$15M
#5
Public · Perth, Western Australia · founded 2001$15.5Mraised▾
Medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company develop and commercializes diagnostic tests known as PromarkerD, for the detection of diabetic kidney disease. Company specialises in the area of proteomics, the industrial scale study of the structure and function of proteins. It also, offers analytical services for research purposes. The technology can be used to identify fingerprints from any biological source, from wheat seeds to human serum.
- Jan 2024Post IPO$4.3M
- Aug 2022Post IPO$5.7M
- May 2022Grant (prize money)$413.5K
- Nov 2021Grant (prize money)$74.6K
#6
Series A · Armadale, Western Australia · founded 2019 · 10 employees$16.5Mraised▾
Provider of a genetic test for determining the health risk of babies. The platform collects the saliva sample from both the parents and provides the genetic influence on the child's health. The results are provided for brain health, heart health, cancer, and overall health. A personalized consultation is provided from fertility experts and genetic counselors on diet, fitness, and health.
- Dec 2023Series A$12M
- Apr 2021Seed$4.5M
#7
Public · Nedlands, Western Australia · founded 2001 · 25 employees$30Mraised▾
Developer of the drug for retinal, liver, and neuro-degenerative diseases. The company offers proprietary CPP (Cell-Penetrating Peptides) technology and RNA-based therapeutics for treating retinal diseases, like Retinitis Pigmentosa responsible for childhood blindness. The company also has a pipeline for neurodegenerative disorders and liver disorders.
- May 2023PE$30M
#8
Public · Melbourne, Victoria · founded 2016$2.7Mraised▾
Developer diagnostic tests for the detection of cancer. The company has developed a minimally invasive blood test for one of the most common forms of cancer. The flagship product is ColoSTAT to detect colorectal cancer.
- Jun 2024Post IPO$2.7M
#9
Funding Raised · Perth, Western Australia · founded 2020 · 20 employees$3Mraised▾
Developer of biosecurity platform and hardware for pathogen testing. The company has developed a technology for testing pathogens. They created the Avicena Sentinel, a molecular diagnostics platform with an hourly screening capacity of thousands of samples. Additionally, they are engaged in the development of microLED-based ultra-low energy optical links.
- Feb 2024Grant (prize money)$3M
#10
Deadpooled · Sydney, New South Wales · founded 2006 · 50 employees$41Mraised▾
Biomarker-based blood tests for early cancer detection. The company's products include Insure ONE which is an in-home collection test for blood in the stool, and COLVERA detects two methylated (silenced) genes, BCAT1 and IKZF1, associated with colorectal tumor growth in circulating tumor DNA.
- Jun 2018Series B$26M
- Mar 2016Series A$15M
#11
Public · Melbourne, Victoria · founded 2015 · 234 employees$25Mraised▾
Developer of theranostic radiopharmaceuticals for imaging and treating cancer. It offers TX250, a Girentuximab antibody with an imaging payload (124-I or 177-Lu), targeting carbonic anhydrase IX, indicated for CCRC, and treatment with 177Lu and NSCLC.
- Nov 2020Post IPO$25M
#12
Public · Toorak, Victoria · founded 2001 · 8 employees$10.1Mraised▾
Developer of RNA-based antisense drugs. The company develops targeted RNA-based antisense drugs. It has four products in its pipeline. Its two lead candidates are in phase III clinical trials for acromegaly and multiple sclerosis. In addition, it has two additional candidates that are in preclinical testing for prostate cancer and asthma.
- Nov 2020Post IPO$7.3M
- Apr 2018Post IPO$581.6K
- Apr 2008Post IPO$2.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Australia
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,442 Australia-affiliated papers.
- University College London180
- Monash University103
- The University of Melbourne89
- The University of Queensland89
- The University of Sydney80
- Gene8→45
- Genome12→45
- Transcriptome2→34
- Identification (biology)2→19
- Immune system1→18
- Disease3→52
- Transcriptome1→21
- Gene2→21
- Biomarker1→20
- Cancer3→21
- Disease4→53
- Identification (biology)1→12
- Genome1→12
- Genomics1→10
- Diabetes mellitus3→11
Where bioinformatics is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.